ClinicalTrials.Veeva

Menu

A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)

Amgen logo

Amgen

Status

Completed

Conditions

Atherosclerotic Cardiovascular Disease

Treatments

Other: Lp(a) Screening

Study type

Interventional

Funder types

Industry

Identifiers

NCT05378529
20210057

Details and patient eligibility

About

The purpose of this study is to characterize the distribution of lipoprotein(a) (Lp(a)) levels among participants with a history of ASCVD as defined by their medical history and is 2-fold:

  • Evaluate the distribution of Lp(a) value in the overall participants with documented history of ASCVD
  • Evaluate the distribution of Lp(a) value in participants with documented history of ASCVD by demographics and regions

Enrollment

39,480 patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Signed informed consent
  • History of ASCVD

Exclusion criteria

  • Participants known to be currently receiving investigational drug in a clinical study
  • Participants with a diagnosis of end-stage renal disease or requiring dialysis
  • Participants who have received lipoprotein apheresis to reduce Lp(a) within 3 months prior to enrollment

Trial design

Primary purpose

Basic Science

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

39,480 participants in 1 patient group

Participants with history of ASCVD
Other group
Description:
Participants with history of ASCVD with known or unknown Lp(a) values.
Treatment:
Other: Lp(a) Screening

Trial contacts and locations

737

Loading...

Central trial contact

Amgen Call Center

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems